Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells 2,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the completion of the transaction, the chief executive officer owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

JAZZ stock traded down $0.83 during mid-day trading on Thursday, reaching $240.48. 1,029,482 shares of the company traded hands, compared to its average volume of 956,914. The company has a fifty day moving average price of $249.38 and a 200-day moving average price of $223.09. Jazz Pharmaceuticals PLC has a 52-week low of $123.88 and a 52-week high of $266.38. The company has a market capitalization of $15.61 billion, a P/E ratio of 16.58, a P/E/G ratio of 0.22 and a beta of 0.36. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s revenue was up 15.5% compared to the same quarter last year. During the same quarter last year, the business posted ($8.25) earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sequoia Financial Advisors LLC grew its position in Jazz Pharmaceuticals by 9.4% during the second quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the specialty pharmaceutical company’s stock valued at $1,091,000 after acquiring an additional 389 shares during the last quarter. Tidal Investments LLC lifted its holdings in shares of Jazz Pharmaceuticals by 8.3% in the 2nd quarter. Tidal Investments LLC now owns 21,028 shares of the specialty pharmaceutical company’s stock worth $5,067,000 after acquiring an additional 1,615 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $386,000. Integrated Wealth Concepts LLC boosted its stake in shares of Jazz Pharmaceuticals by 27.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 1,762 shares of the specialty pharmaceutical company’s stock valued at $425,000 after purchasing an additional 377 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 15.7% during the 2nd quarter. NewEdge Advisors LLC now owns 2,285 shares of the specialty pharmaceutical company’s stock valued at $551,000 after purchasing an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JAZZ. Bank of America upped their price target on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Piper Sandler upped their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $285.50.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.